In addition, BRD4 inhibitors, such as JQ1, have demonstrated success in targeting MYC-regulated super-enhancer networks in RMS, thereby disrupting transcriptional drivers of tumor proliferation [25]. The gene discussed is MYC; the disease is neoplasm.